Back to Directory
Last Updated: 04/06/2026
Neuro-Bio
Oxford
Founded 2013
Novel peptide-based therapeutics and biomarkers for neurodegeneration
Neuro-Bio is a preclinical-stage biotechnology company developing a first-in-class therapeutic approach to Alzheimer's disease and related neurodegenerative disorders.
Its research centres on T14, a 14 amino acid bioactive peptide derived from acetylcholinesterase, which the company has identified as a potential driver of neurodegeneration in the adult brain.
Neuro-Bio is pursuing both a therapeutic programme targeting T14 activity and a companion blood-based diagnostic to detect its presence as a biomarker of early disease.